Latest News
Clinigen Closes EUR 7.5m Acquisition of Swiss Pharmaceutical Business iQone Healthcare
Friday 12 October 2018

12 October 2018 - UK-based pharmaceutical company Clinigen Group plc (AIM: CLIN) has closed the acquisition of Switzerland-based pharmaceutical business iQone Healthcare Holding for EUR 7.5m, the company said.

Clinigen is acquiring iQone on a cash free, debt free basis for a total initial consideration of EUR 7.5m (GBP 6.7m) (USD 8.7m), made up of EUR 5.0m in cash and EUR 2.5m in new Clinigen shares, with an additional potential deferred consideration based on the achievement of certain future EBITDA targets.

iQone adds capability to Clinigen's Unlicensed and Commercial divisions, whilst also offering the Group a platform to support and expand its activities in mainland Europe.

It also provides iQone with resources and access to an extensive customer and product base to accelerate its growth.

iQone is based near Geneva with operations across Europe.

It has medical and commercial operations in France, Germany, Italy, Spain and Switzerland. Its team has extensive experience in the set up and delivery of both Managed Access Programmes and commercial solutions across Europe.

Clinigen Group plc is a combination of businesses focussed on providing ethical access to medicines. Its mission is to deliver the right medicine to the right patient at the right time through three areas of global medicine supply; clinical trial, unlicensed and licensed medicines.
Date Published: 12/10/2018
Target: iQone Healthcare Holding
Country: Switzerland
Deal Size: 8.7m (USD)
Sector: Pharmaceuticals
Type: Corporate acquisition
Financing: Cash and Stock
Status: Agreed
Buyer: Clinigen Group
Terms of the deal were not disclosed